Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 30 September 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

IBD-associated pyoderma gangrenosum in the biologic era

The latest issue of Alimentary Pharmacology & Therapeutics reviews the response to therapy for inflammatory bowel disease-associated pyoderma gangrenosum in the biologic era.

News image

Pyoderma gangrenosum in inflammatory bowel disease is uncommon and therapeutically challenging.

Its treatment remains poorly characterized due to limited individual center or practitioner experience.

No large series are reported since 2003, yet inflammatory bowel disease treatment has changed substantially.

Dr Agarwal and colleagues from Australia provided an up-to-date review of the published treatment efficacy of currently available therapies for inflammatory bowel disease-related pyoderma gangrenosum in the biologic era.

Systematic review of cases published post-2003 since the broad availability of anti-tumour necrosis factor-alpha therapy.

In 12%, trauma preceded pyoderma gangrenosum
Alimentary Pharmacology & Therapeutics

Cases which did not have coexistent inflammatory bowel disease, were non-English language, of paediatric age or without data on response to therapy were excluded.

The team identified 60 cases, of which 55% were female, 50% had ulcerative colitis, 45% had Crohn's disease, and 5% inflammatory bowel disease.

At pyoderma gangrenosum diagnosis, 58% had active, and only 15% inactive inflammatory bowel disease, with 27% with inflammatory bowel disease activity unspecified.

The research team found that predominant sites were lower limb and peristomally, and 42% had multiple lesions.

In 12%, trauma preceded pyoderma gangrenosum.

The researchers found that in 42%, new pyoderma gangrenosum appeared whilst on inflammatory bowel disease-specific therapy, whilst 28% were on no therapy and in 30%, inflammatory bowel disease therapy was unspecified.

Of patients on no therapy at pyoderma gangrenosum onset, the team found that 16 healed, of which 7 had first- and eight with second-line therapy.

In total, 34 out of 60 patients received infliximab, 4 received adalimumab, 2 had both, with 33 responding to one or the other.

The team observed no correlation of pyoderma gangrenosum duration or size with healing times.

Dr Agarwal's team concludes, "Pyoderma gangrenosum appears predominantly during active inflammatory bowel disease and is seen equally in Crohn's disease and ulcerative colitis."

"New pyoderma gangrenosum may be a manifestation of recrudescent inflammatory bowel disease or it follow trauma."

"Anti-TNFa therapy as a first-line agent for pyoderma gangrenosum should be considered, as it appears to be highly effective."

Aliment Pharmacol & Ther 2013: 38(6): 563–572
11 September 2013

Go to top of page Email this page Email this page to a colleague

 30 September 2016 
Gluten breakdown and immunogenicity in celiac disease
 30 September 2016 
Noninvasive detection of NASH
 30 September 2016 
CEA levels to detect recurrent colorectal cancer
 29 September 2016 
Biologic therapies in IBD
 29 September 2016 
Predicting the prognosis of gastric cancer
 29 September 2016 
Predicting symptomatic outcomes in GERD
 28 September 2016 
Hep C virus RNA in liver explants
 28 September 2016 
Global trends in pancreatic cancer mortality
 28 September 2016 
Heterogeneity in endoscopic treatment of Crohn’s
 27 September 2016 
Non-invasive tests of NAFLD
 27 September 2016 
Fecal microbiota transplantation for C.diff in IBD
 27 September 2016 
Fast-track colorectal surgery influences outcomes
 26 September 2016 
Preventing cirrhosis in Hep C with fibrosis
 26 September 2016 
Body image after abdominoperineal excision for rectal cancer
 26 September 2016 
Gastric cancer risk in intestinal metaplasia of the stomach
 23 September 2016 
Sleep quality in nonalcoholic cirrhotic patients
 23 September 2016 
Exercise for NAFLD
 23 September 2016 
BMI history and fatty liver
 22 September 2016 
Predicting small-bowel Crohn’s disease
 22 September 2016 
Colectomy outcomes for ulcerative colitis
 22 September 2016 
Technology vs intervention for weight loss
 21 September 2016 
Employment status and IBD
 21 September 2016 
Cardiopulmonary exercise testing in liver transplant candidates
 21 September 2016 
Patients vs providers on nutrition in IBD
 20 September 2016 
Improving healthcare systems for viral Hepatitis
 20 September 2016 
GI benefits of COX-2 selective inhibitors
 20 September 2016 
Predicting relapse in Crohn's
 19 September 2016 
Prevalence of esophageal cancer in Barrett's
 19 September 2016 
Fecal microbiota transplantation and CDI in IBD
 19 September 2016 
Antibiotic resistance in Helicobacter pylori
 16 September 2016 
Low-residue diet before colonoscopy and bowel cleansing
 16 September 2016 
Genome-wide association in gastric cancer
 16 September 2016 
H. pylori in children with asthma
 15 September 2016 
Improving survival in cholangitis-associated septic shock
 15 September 2016 
Colorectal cancer survival and hospital volumes
 15 September 2016 
Primary sclerosing cholangitis and IBD
 14 September 2016 
Intestinal malabsorption and olmesartan
 14 September 2016 
Infection reduction strategy after colorectal resection
 14 September 2016 
Predicting long-term infliximab use in Crohn's
 13 September 2016 
Predicting survival in refractory celiac disease
 13 September 2016 
Cancer risk stratification in Barrett’s
 13 September 2016 
Screening vs non-screening colonoscopy
 12 September 2016 
Screening in familial colorectal cancer
 12 September 2016 
Metformin improves survival in pancreatic ductal cancer
 12 September 2016 
Consent guidelines for GI endoscopy procedures
 09 September 2016 
Development of IBS
 09 September 2016 
Safe and effective treatment for NASH
 09 September 2016 
Scale for stool measurement in diarrhea-IBS
 08 September 2016 
Prognostic factors for infliximab in Crohn's
 08 September 2016 
Chronic Hep B vs chronic Hep C and mortality
 08 September 2016 
Hematological malignancies in IBD
 07 September 2016 
IBD relapse during pregnancy
 07 September 2016 
New treatments for ulcerative colitis
 07 September 2016 
Alternative to nucleic acid testing in HCV
 06 September 2016 
EHealth technologies in IBD
 06 September 2016 
Endoscopy clinic no-shows
 06 September 2016 
Risk of infection after elective colorectal surgery
 05 September 2016 
Esophageal impedance monitoring
 05 September 2016 
Family history and IBD clinical course
 05 September 2016 
Biomarker for IBD and GI cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us